Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 10, 2008. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
| Metric | Value |
|---|---|
| Shares Purchased | 1,740,000 |
| Purchase Price | 1,066 pence per share |
| Treasury Shares Held | 484,194,158 |
| Treasury Percentage of Voting Rights | 9.09% |
| Shares in Issue (Excluding Treasury) | 5,326,792,545 |
Material Changes
On June 10, 2008, the Company purchased 1,740,000 Ordinary shares. These shares were cancelled immediately following the purchase. Consequently, the total number of shares held in Treasury increased to 484,194,158, representing 9.09% of the total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming the execution of a share buyback in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,326,792,545) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on voting rights (9.09%).
- Note that the 1,740,000 shares purchased on June 10, 2008, have been cancelled and are no longer outstanding.